FDA approves lenacapavir, a lower-cost HIV prevention drug, as structural biology tools advance

The US Food and Drug Administration has approved lenacapavir, an HIV prevention drug intended to be more affordable. The article describes how its binding pocket on the viral capsid was examined using virtual reality and molecular simulations. The author recounts years of resistance-mutation analysis and notes that VR allows faster comparison of binding energies across variants. Simulations of the Q67H resistance mutation revealed conformational changes that existing inhibitors may not cover, informing design guidance for next-generation capsid inhibitors. The piece argues that visualizing molecular data in immersive form helps researchers gain new insights more quickly.